Developer docs
API playgroundTry for free, no card

Search company profiles

ViroPharma

Full company profile

uuid0009h9r

Namestring
ViroPharma
Websiteurl
viropharma.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

ViroPharma is a U.S.-headquartered biopharmaceutical company founded in 1994 and based in Exton, Pennsylvania. Its stated function is the development and commercialization of products that address serious diseases, positioning it as a specialty biopharma firm focused on therapies for conditions with limited treatment options. The company builds its commercial and pipeline portfolio through proprietary drug development supplemented by targeted acquisitions of complementary specialty assets, including Lev Pharmaceuticals (hereditary angioedema franchise, acquired 2008), Auralis (respiratory/specialty disease pipeline, acquired 2010), and DuoCort Pharma (replacement therapy, acquired 2011).

ViroPharma's revenue mechanics are consistent with a branded specialty pharma model: it monetizes approved, patent-protected therapeutics sold into healthcare channels (physicians, specialty pharmacies, hospitals, and payers) treating patients with serious or rare diseases. The reported employee base of 5,001–10,000 indicates a substantial commercial and operational footprint supporting sales, manufacturing oversight, regulatory affairs, and post-marketing pharmacovigilance. The company is listed in input data as privately held and for-profit, with the leadership bench anchored by CEO Vincent J. Milano. Early venture backing from Frazier Healthcare Partners (1996) preceded a multi-year acquisition-led expansion of the therapeutic pipeline.

The company operates as a subsidiary-level entity of a larger global pharmaceutical group (Takeda, per public corporate context), though specific go-to-market detail — distribution partners, payer concentration, geographic mix, and pricing tiers — is not disclosed in the supplied source material. Source commentary explicitly notes a data gap on ownership-specific information within the supplied corpus.

Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersExton, United States
HQ citystring
Exton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical development, rare disease therapeutics, specialty pharmaceutical products, infectious disease drugs, clinical drug development
Industry2 codes
1Infectious Disease & Antimicrobials Pharmaceuticals
CodeHLAIAAAGPrimaryYes
2Primary Care & General Medicine Pharmaceuticals
CodeHLAIAAAAPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
Product category
Specialty Pharmaceuticals
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ViroPharma is a biopharmaceutical company that develops and commercializes pharmaceutical products addressing serious diseases. The company built its portfolio through internal development and acquisitions of complementary specialty therapeutics developers (DuoCort Pharma, Auralis, and Lev Pharmaceuticals), focusing on treatments for serious infectious and rare disease indications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Pharmaceutical Products for Serious Diseases
CategorySpecialty Pharmaceuticals
Description

Therapeutic products developed and commercialized for serious diseases, sold to healthcare providers, hospital systems, and specialty pharmacy channels. The portfolio was expanded via acquisitions of specialty therapeutics developers including DuoCort Pharma, Auralis, and Lev Pharmaceuticals.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1BioCryst Pharmaceuticals
TypeDirect peer
Description

Specialty biopharma developing oral therapies for rare/serious diseases, including HAE (hereditary angioedema) — directly overlapping with ViroPharma's serious-disease / HAE franchise via Cinryze.

2Pharming Group
TypeDirect peer
Description

Develops and commercializes a plasma-free C1-esterase inhibitor for hereditary angioedema, the same mechanism as ViroPharma's Cinryze — a head-to-head comparator in the HAE acute-treatment market.

3CSL Behring
TypeDirect peer
Description

Plasma-derived biologics franchise including a C1-esterase inhibitor for HAE, matching ViroPharma's plasma-derived biologic platform in both therapeutic area and modality.

4Shire (acquired by Takeda)
TypeBroad incumbent
Description

Rare-disease specialty pharma that ultimately acquired ViroPharma; operates a much broader rare-disease/immunology portfolio but overlaps substantively in HAE and serious-disease commercialization.

5The Medicines Company
TypeDirect peer
Description

Specialty biopharma historically focused on infectious-disease and cardiovascular therapeutics — directly comparable profile to ViroPharma's serious-disease branded-pharma model.

6Nabriva Therapeutics
TypeDirect peer
Description

Antibiotic developer commercializing lefamulin for community-acquired bacterial pneumonia — comparable specialty anti-infective commercialization model to ViroPharma's anti-infective franchise.

7Paratek Pharmaceuticals
TypeDirect peer
Description

Specialty anti-infective developer (omadacycline / Nuzyra) pursuing serious-infection indications — directly comparable therapeutic-area focus and specialty-pharma commercialization model.

8Seres Therapeutics
TypeDirect peer
Description

Microbiome therapeutics company with a C. difficile infection franchise (VOWST) — overlaps with ViroPharma's branded anti-infective positioning around serious GI infectious diseases.

9Tetraphase Biosciences (acquired by La Jolla Pharmaceutical Company)
TypeDirect peer
Description

Developer of eravacycline (Xerava) for serious bacterial infections including complicated intra-abdominal infections — directly comparable branded anti-infective specialty model.

10Cubist Pharmaceuticals (acquired by Merck)
TypeBroad incumbent
Description

Pre-acquisition specialist in antibiotics for serious infections (daptomycin/Cubicin) — strongly overlapping therapeutic-area focus with ViroPharma's infectious-disease franchise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ViroPharma

Specialty Pharmaceuticalsviropharma.com

What ViroPharma does

ViroPharma is a U.S.-headquartered biopharmaceutical company founded in 1994 and based in Exton, Pennsylvania. Its stated function is the development and commercialization of products that address serious diseases, positioning it as a specialty biopharma firm focused on therapies for conditions with limited treatment options. The company builds its commercial and pipeline portfolio through proprietary drug development supplemented by targeted acquisitions of complementary specialty assets, including Lev Pharmaceuticals (hereditary angioedema franchise, acquired 2008), Auralis (respiratory/specialty disease pipeline, acquired 2010), and DuoCort Pharma (replacement therapy, acquired 2011).

ViroPharma's revenue mechanics are consistent with a branded specialty pharma model: it monetizes approved, patent-protected therapeutics sold into healthcare channels (physicians, specialty pharmacies, hospitals, and payers) treating patients with serious or rare diseases. The reported employee base of 5,001–10,000 indicates a substantial commercial and operational footprint supporting sales, manufacturing oversight, regulatory affairs, and post-marketing pharmacovigilance. The company is listed in input data as privately held and for-profit, with the leadership bench anchored by CEO Vincent J. Milano. Early venture backing from Frazier Healthcare Partners (1996) preceded a multi-year acquisition-led expansion of the therapeutic pipeline.

The company operates as a subsidiary-level entity of a larger global pharmaceutical group (Takeda, per public corporate context), though specific go-to-market detail — distribution partners, payer concentration, geographic mix, and pricing tiers — is not disclosed in the supplied source material. Source commentary explicitly notes a data gap on ownership-specific information within the supplied corpus.

ViroPharma firmographics

Firmographics
Name
ViroPharma
Website
https://viropharma.com
Company type
Private
Founded year
1994
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

ViroPharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
akta.pro primary industry
Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
akta.pro secondary industry
Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

  • Biopharmaceutical development
  • Rare disease therapeutics
  • Specialty pharmaceutical products
  • Infectious disease drugs
  • Clinical drug development

Where ViroPharma is headquartered

Location

Headquarters

HQ city
Exton
HQ country
United States
HQ region
North America

Markets served

ViroPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

ViroPharma product offering

Product offering

Core offering

ViroPharma is a biopharmaceutical company that develops and commercializes pharmaceutical products addressing serious diseases. The company built its portfolio through internal development and acquisitions of complementary specialty therapeutics developers (DuoCort Pharma, Auralis, and Lev Pharmaceuticals), focusing on treatments for serious infectious and rare disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Products for Serious Diseases Therapeutic products developed and commercialized for serious diseases, sold to healthcare providers, hospital systems, and specialty pharmacy channels. The portfolio was expanded via acquisitions of specialty therapeutics developers including DuoCort Pharma, Auralis, and Lev Pharmaceuticals.

Companies that use ViroPharma

Customer profile

Ideal customer profiles1 record

ViroPharma technology and API

Technology

Technology focussed No

API detail

API docs
API detail

Core technology

AI maturity

App detail

ViroPharma partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

ViroPharma competitors and assessment

Company assessment

Direct peers

  • BioCryst Pharmaceuticals: Specialty biopharma developing oral therapies for rare/serious diseases, including HAE (hereditary angioedema) — directly overlapping with ViroPharma's serious-disease / HAE franchise via Cinryze.
  • Pharming Group: Develops and commercializes a plasma-free C1-esterase inhibitor for hereditary angioedema, the same mechanism as ViroPharma's Cinryze — a head-to-head comparator in the HAE acute-treatment market.
  • CSL Behring: Plasma-derived biologics franchise including a C1-esterase inhibitor for HAE, matching ViroPharma's plasma-derived biologic platform in both therapeutic area and modality.
  • The Medicines Company: Specialty biopharma historically focused on infectious-disease and cardiovascular therapeutics — directly comparable profile to ViroPharma's serious-disease branded-pharma model.
  • Nabriva Therapeutics: Antibiotic developer commercializing lefamulin for community-acquired bacterial pneumonia — comparable specialty anti-infective commercialization model to ViroPharma's anti-infective franchise.
  • Paratek Pharmaceuticals: Specialty anti-infective developer (omadacycline / Nuzyra) pursuing serious-infection indications — directly comparable therapeutic-area focus and specialty-pharma commercialization model.
  • Seres Therapeutics: Microbiome therapeutics company with a C. difficile infection franchise (VOWST) — overlaps with ViroPharma's branded anti-infective positioning around serious GI infectious diseases.
  • Tetraphase Biosciences (acquired by La Jolla Pharmaceutical Company): Developer of eravacycline (Xerava) for serious bacterial infections including complicated intra-abdominal infections — directly comparable branded anti-infective specialty model.

Broad incumbents

  • Shire (acquired by Takeda): Rare-disease specialty pharma that ultimately acquired ViroPharma; operates a much broader rare-disease/immunology portfolio but overlaps substantively in HAE and serious-disease commercialization.
  • Cubist Pharmaceuticals (acquired by Merck): Pre-acquisition specialist in antibiotics for serious infections (daptomycin/Cubicin) — strongly overlapping therapeutic-area focus with ViroPharma's infectious-disease franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

ViroPharma social profiles

Digital presence

ViroPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ViroPharma leadership team

Management profile

Number of profiles

Profiles1 record

ViroPharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ViroPharma M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViroPharma

What does ViroPharma do?

ViroPharma is a biopharmaceutical company that develops and commercializes pharmaceutical products addressing serious diseases. The company built its portfolio through internal development and acquisitions of complementary specialty therapeutics developers (DuoCort Pharma, Auralis, and Lev Pharmaceuticals), focusing on treatments for serious infectious and rare disease indications.

When was ViroPharma founded?

ViroPharma was founded in 1994. It employs 5,001 to 10,000 people.

Where is ViroPharma based?

ViroPharma is headquartered in Exton, United States, in the North America region.

Who are ViroPharma's main competitors?

Direct peers on record are BioCryst Pharmaceuticals, Pharming Group, CSL Behring, The Medicines Company, Nabriva Therapeutics, Paratek Pharmaceuticals, Seres Therapeutics and Tetraphase Biosciences (acquired by La Jolla Pharmaceutical Company). Broad incumbents are Shire (acquired by Takeda) and Cubist Pharmaceuticals (acquired by Merck).

What industry is ViroPharma in?

ViroPharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireViropharma Partnering Deals and Alliances 2010 to 2017Reportbuyer has published a market research report detailing Viropharma's partnering deals and alliances from 2010 to 2017. The report provides an in-depth analysis of the company's business development activities, including deal structures, contract documents, and strategic partnerships within the life sciences sector.GlobeNewswireViroPharma Incorporated Announces Completion of OfferingViroPharma completed its underwritten public offering of 10,350,000 shares at $16.75 per share, raising approximately $163.8 million in net proceeds. The company will use the funds for working capital and general corporate purposes, and may also repay its 6% subordinated convertible notes due March 2007.GlobeNewswireViroPharma Incorporated Announces Exercise of Option to Purchase Additional SecuritiesViroPharma's underwriters exercised their option to purchase 1,350,000 additional shares in its public offering, with the offering closing December 12, 2005. The company expects approximately $163.8 million in net proceeds for working capital and general corporate purposes, including potential repayment of its 6% subordinated convertible notes due March 2007.GlobeNewswireViroPharma Incorporated Prices Public Offering of Common StockViroPharma priced an underwritten public offering of 9 million shares at $16.75 per share, generating about $142 million in net proceeds. The company will use the funds for working capital, general corporate purposes, and potentially to repay its 6% subordinated convertible notes due March 2007.GlobeNewswireViroPharma Incorporated Announces Public Offering of Common StockViroPharma announced a public offering of 7 million common shares, with a 30-day option for up to 1.05 million more. Proceeds will fund working capital, general corporate purposes, and possibly repay 6% subordinated convertible notes due March 2007. Goldman Sachs will act as sole book-running manager.GlobeNewswireViroPharma Incorporated Reports Second Quarter and Six-Month 2005 Financial ResultsViroPharma reported record Vancocin net sales of $28.8 million for Q2 2005 and $49.9 million for six months, with operating income of $18.7 million and $36.1 million. Net income turned positive to $5.0 million and $22.4 million, and debt principal was reduced by $97.6 million through June 30.GlobeNewswireViroPharma Incorporated Reports First Quarter 2005 Financial Results and Increases 2005 Vancocin Pulvules Net Sales GuidanceViroPharma reported Q1 2005 net income of $17.4 million, up from a $16.6 million loss in Q1 2004, with Vancocin Pulvules net sales of $21.1 million. The company updated its 2005 guidance, projecting net product sales of $74–79 million, up 37–46% from 2004.GlobeNewswireViroPharma Incorporated Completes Acquisition of U.S. Vancocin BrandViroPharma completed its acquisition of all U.S. rights to manufacture, market, and sell Vancocin Pulvules, an oral vancomycin capsule, from Eli Lilly. The company will commercialize the product for treating enterocolitis and antibiotic-associated colitis. ViroPharma continues its focus on viral diseases like CMV and hepatitis C.GlobeNewswireViroPharma Incorporated Reports Third Quarter Financial ResultsViroPharma reported a net loss of $3.3 million for the quarter ended September 30, 2004, down from $15.8 million in 2003, with net loss per share of $0.13. The nine-month net loss was $25.3 million, down from $29.8 million, and cash and equivalents stood at $96.6 million.GlobeNewswireViroPharma Incorporated Receives Antitrust Clearance For U.S. Vancocin Brand AcquisitionViroPharma received antitrust clearance for its U.S. acquisition of Eli Lilly's Vancocin Pulvules brand. The deal includes an $116 million upfront payment, with closing expected in the week of November 8, 2004. Lilly will receive royalties on annual net sales.